Therapy Areas: Cardiovascular
Haya Therapeutics Receives Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies
4 May 2022 - - Swiss Innovation Agency Innosuisse is supporting two research collaboration projects between Swiss precision medicines developer Haya Therapeutics, SA and the University of Bern, University Hospital of Bern and Lausanne University Hospital, Haya said.

Innosuisse is funding 50% of the total project costs of approximately CHF 3.1m (USD 3.3m).

The first project will advance Haya's lead program, an antisense oligonucleotide targeting the lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart.

In collaboration with the Department for BioMedical Research at University of Bern and the Department of Cardiology at University Hospital of Bern (Inselspital), the two-year project will be focused on dosing studies, pharmacodynamics, and pharmacokinetics for this first-in-class therapeutic target for the potential treatment of non-obstructive hypertrophic cardiomyopathy.

The study also includes cardiac MRI read-outs to provide evidence for efficacy and translatability of the therapeutic approach and advancing it towards the clinic and in-need patients.

Haya's second project will aim to develop a next-generation oncology therapy targeting cancer-associated fibroblasts for the treatment of squamous cell carcinoma.

Through a partnership with Lausanne University Hospital (Centre hospitalier universitaire vaudois, CHUV), the collaborators will use Haya's proprietary drug discovery engine, DiscoverHaya, to identify oncology-associated fibroblast-specific lncRNAs for the development of a precision RNA-targeted therapy.

Haya Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer.

The company's discovery engine focuses on long non-coding RNAs (lncRNAs) within the "dark matter" of the human genome key tissue and cell-specific drivers of fibrosis and other disease processes to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.

Haya's lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown in preclinical testing the ability to halt and potentially reverse the fibrotic processes underlying heart failure.

The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers.


Related Headlines